In vivo administration of interleukin 2 plus T cell-depleted syngeneic marrow prevents graft-versus-host disease mortality and permits alloengraftment

doi:10.1084/jem.171.3.645

This Article

	Full Text (PDF, 933K)
	Alert me when this article is cited
	Citation Map

Services

	Email this article
	Similar articles in this journal
	Similar articles in PubMed
	Alert me to new content in the JEM
	Download to citation manager

Citing Articles

	Citing Articles via HighWire
	Citing Articles via CrossRef
	Citing Articles via Google Scholar

Google Scholar

	Articles by Sykes, M.
	Articles by Sachs, D. H.
	Search for Related Content

PubMed

	PubMed Citation
	Articles by Sykes, M.
	Articles by Sachs, D. H.


Social Bookmarking

	What's this?

ARTICLES

In vivo administration of interleukin 2 plus T cell-depleted syngeneic marrow prevents graft-versus-host disease mortality and permits alloengraftment

M Sykes, ML Romick, KA Hoyles and DH Sachs
Transplantation Biology Section, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892.

Previous work from this laboratory has demonstrated that T cell- depleted (TCD) syngeneic marrow can delay, but not prevent, the mortality from acute graft-vs.-host disease (GVHD) caused by MHC- mismatched lymphoid cells administered to lethally irradiated mice. We demonstrate here that a protective effect against GVHD is also observed after in vivo treatment with IL-2. Administration of 10,000-50,000 U of IL-2 twice daily for the first 5 d after bone marrow transplantation markedly reduced the mortality from both acute and chronic GVHD induced across complete MHC barriers in lethally irradiated mice, and frequently led to long-term survival. Complete allogeneic reconstitution was demonstrated in all long-term survivors of this treatment regimen. While either IL-2 or TCD syngeneic marrow administered alone was protective in some experiments, the maximal protective effect was observed after administration of both IL-2 and TCD syngeneic marrow, especially when the effects of IL-2 were suboptimal. The timing of IL-2 administration was critical to this beneficial effect, since a delay of 7 d in commencing IL-2 treatment was associated with accelerated GVHD mortality. This new approach to the prevention of GVHD permits the administration of allogeneic T cells, and may therefore avoid the increased incidence of graft failure and loss of antileukemic effects associated with the T cell depletion of allogeneic marrow, which is otherwise required for the prevention of GVHD.
Add to CiteULike CiteULike Add to Complore Complore Add to Connotea Connotea Add to Del.icio.us Del.icio.us Add to Digg Digg Facebook Add to Reddit Reddit Add to Technorati Technorati Twitter What's this?

This article has been cited by other articles:

Kurtz, J., Raval, F., Vallot, C., Der, J., Sykes, M. (2009). CTLA-4 on alloreactive CD4 T cells interacts with recipient CD80/86 to promote tolerance. Blood 113: 3475-3484 [Abstract] [Full Text]
Zorn, E., Nelson, E. A., Mohseni, M., Porcheray, F., Kim, H., Litsa, D., Bellucci, R., Raderschall, E., Canning, C., Soiffer, R. J., Frank, D. A., Ritz, J. (2006). IL-2 regulates FOXP3 expression in human CD4+CD25+ regulatory T cells through a STAT-dependent mechanism and induces the expansion of these cells in vivo. Blood 108: 1571-1579 [Abstract] [Full Text]
Sun, K., Wilkins, D. E. C., Anver, M. R., Sayers, T. J., Panoskaltsis-Mortari, A., Blazar, B. R., Welniak, L. A., Murphy, W. J. (2005). Differential effects of proteasome inhibition by bortezomib on murine acute graft-versus-host disease (GVHD): delayed administration of bortezomib results in increased GVHD-dependent gastrointestinal toxicity. Blood 106: 3293-3299 [Abstract] [Full Text]
Kurtz, J., Shaffer, J., Lie, A., Anosova, N., Benichou, G., Sykes, M. (2004). Mechanisms of early peripheral CD4 T-cell tolerance induction by anti-CD154 monoclonal antibody and allogeneic bone marrow transplantation: evidence for anergy and deletion but not regulatory cells. Blood 103: 4336-4343 [Abstract] [Full Text]
Sun, K., Welniak, L. A., Panoskaltsis-Mortari, A., O'Shaughnessy, M. J., Liu, H., Barao, I., Riordan, W., Sitcheran, R., Wysocki, C., Serody, J. S., Blazar, B. R., Sayers, T. J., Murphy, W. J. (2004). Inhibition of acute graft-versus-host disease with retention of graft-versus-tumor effects by the proteasome inhibitor bortezomib. Proc. Natl. Acad. Sci. USA 101: 8120-8125 [Abstract] [Full Text]
Yang, Y.-G., Qi, J., Wang, M.-G., Sykes, M. (2002). Donor-derived interferon gamma separates graft-versus-leukemia effects and graft-versus-host disease induced by donor CD8 T cells. Blood 99: 4207-4215 [Abstract] [Full Text]
Russell, P. S., Chase, C. M., Sykes, M., Ito, H., Shaffer, J., Colvin, R. B. (2001). Tolerance, Mixed Chimerism, and Chronic Transplant Arteriopathy. J. Immunol. 167: 5731-5740 [Abstract] [Full Text]
Ito, H., Kurtz, J., Shaffer, J., Sykes, M. (2001). CD4 T Cell-Mediated Alloresistance to Fully MHC-Mismatched Allogeneic Bone Marrow Engraftment Is Dependent on CD40-CD40 Ligand Interactions, and Lasting T Cell Tolerance Is Induced by Bone Marrow Transplantation with Initial Blockade of this Pathway. J. Immunol. 166: 2970-2981 [Abstract] [Full Text]
Wekerle, T., Kurtz, J., Sayegh, M. H., Ito, H., Wells, A. D., Bensinger, S., Shaffer, J., Turka, L. A., Sykes, M. (2001). Peripheral Deletion After Bone Marrow Transplantation with Costimulatory Blockade Has Features of Both Activation-Induced Cell Death and Passive Cell Death. J. Immunol. 166: 2311-2316 [Abstract] [Full Text]
Nikolic, B., Cooke, D. T., Zhao, G., Sykes, M. (2001). Both {{gamma}}{{delta}} T Cells and NK Cells Inhibit the Engraftment of Xenogeneic Rat Bone Marrow Cells and the Induction of Xenograft Tolerance in Mice. J. Immunol. 166: 1398-1404 [Abstract] [Full Text]
Wekerle, T., Sayegh, M. H., Hill, J., Zhao, Y., Chandraker, A., Swenson, K. G., Zhao, G., Sykes, M. (1998). Extrathymic T Cell Deletion and Allogeneic Stem Cell Engraftment Induced with Costimulatory Blockade Is Followed by Central T Cell Tolerance. JEM 187: 2037-2044 [Abstract] [Full Text]
Dey, B. R., Yang, Y.-G., Szot, G. L., Pearson, D. A., Sykes, M. (1998). Interleukin-12 Inhibits Graft-Versus-Host Disease Through an Fas-Mediated Mechanism Associated With Alterations in Donor T-Cell Activation and Expansion. Blood 91: 3315-3322 [Abstract] [Full Text]
Yang, Y.-G., Sergio, J. J., Pearson, D. A., Szot, G. L., Shimizu, A., Sykes, M. (1997). Interleukin-12 Preserves the Graft-Versus-Leukemia Effect of Allogeneic CD8 T Cells While Inhibiting CD4-Dependent Graft-Versus-Host Disease in Mice. Blood 90: 4651-4660 [Abstract] [Full Text]